A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment
NCT06192563
·
clinicaltrials.gov ↗
UNKNOWN
Status
150
Enrollment
INDUSTRY
Sponsor class
Conditions
Dermatitis Atopic
Interventions
DRUG:
Dupilumab
Sponsor
Sanofi